Towards a mechanism-based approach for the prediction of nongenotoxic carcinogenic potential of agrochemicals.


Journal

Critical reviews in toxicology
ISSN: 1547-6898
Titre abrégé: Crit Rev Toxicol
Pays: England
ID NLM: 8914275

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 26 11 2020
medline: 19 5 2021
entrez: 25 11 2020
Statut: ppublish

Résumé

Chemical substances are subjected to assessment of genotoxic and carcinogenic effects before being marketed to protect man and the environment from health risks. For agrochemicals, the long-term rodent carcinogenicity study is currently required from a regulatory perspective. Although it is the current mainstay for the detection of nongenotoxic carcinogens, carcinogenicity studies are shown to have prominent weaknesses and are subject to ethical and scientific debate. A transition toward a mechanism-based weight-of-evidence approach is considered a requirement to enhance the prediction of carcinogenic potential for environmental (agro)chemicals. The resulting approach should make optimal use of innovative (computational) tools and be less animal demanding. To identify the various mode of actions (MOAs) underlying the nongenotoxic carcinogenic potential of agrochemicals, we conducted an extensive analysis of 411 unique agrochemicals that have been evaluated for carcinogenicity by the United States Environmental Protection Agency (US EPA) and the European Chemicals Agency (ECHA). About one-third of these substances could be categorized as nongenotoxic carcinogens with an average of approximately two tumor types per substance, observed in a variety of organs. For two-third of the tumor cases, an underlying MOA (network) could be identified. This analysis demonstrates that a limited set of MOA (networks) is underlying nongenotoxic carcinogenicity of agrochemicals, illustrating that the transition toward a MOA-driven approach appears manageable. Ultimately the approach should cover relevant MOAs and its associated key events; this will also facilitate the evaluation of the human relevance. This manuscript describes the results of the analysis while identifying knowledge gaps and necessities to achieve a mechanism-based weight-of-evidence approach.

Identifiants

pubmed: 33236972
doi: 10.1080/10408444.2020.1841732
doi:

Substances chimiques

Agrochemicals 0
Carcinogens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

725-739

Auteurs

Harm Heusinkveld (H)

Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Hedwig Braakhuis (H)

Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Robin Gommans (R)

Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Phil Botham (P)

Syngenta Crop Protection, Bracknell, UK.

Marco Corvaro (M)

Corteva Agriscience, Rome, Italy.

Jan Willem van der Laan (JW)

Medicines Evaluation Board, Utrecht, the Netherlands.

Dick Lewis (D)

Syngenta Crop Protection, Bracknell, UK.

Federica Madia (F)

European Commission, Joint Research Centre (JRC), Ispra, Italy.

Irene Manou (I)

European Partnership for Alternative Approaches to Animal Testing (EPAA), Brussels, Belgium.

Frédéric Schorsch (F)

Bayer SAS, Lyon, France.

Gerrit Wolterink (G)

Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Ruud Woutersen (R)

TNO Quality of Life, Zeist, and Wageningen University & Research, Wageningen, the Netherlands.

Raffaella Corvi (R)

European Commission, Joint Research Centre (JRC), Ispra, Italy.

Jyotigna Mehta (J)

ADAMA Agricultural Solutions Ltd, Reading, UK.

Mirjam Luijten (M)

Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH